CXCR4 and plasma cell myeloma: An anti-CXCR4 antibody, or peptides recognizing CXCR4, have also been tested to target cytotoxic substances against cancer stem cells in acute myelogenous leukemia [326], breast cancer cells [327], colorectal cancer cells [328] and multiple myeloma [329].